Is STXS or TMDX more undervalued in 2026?

CirclFi compares Stereotaxis, Inc. (STXS) and TransMedics Group, Inc. (TMDX) using 13 institutional-grade valuation models. STXS has a Quality of Company score of 6.0/10 while TMDX scores 9.7/10.

Which is a better buy — STXS or TMDX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do STXS and TMDX valuations compare?

STXS at $1.98 and TMDX at $67.20 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

STXS vs TMDX Valuation Comparison 2026 — Intrinsic Value Analysis

STXS

Electromedical & Electrotherapeutic Apparatus

Stereotaxis, Inc.

Quality

6.0

out of 10

Value Trap

LOW

Price

$1.98

Last close

Models

10/13

Active

TMDX

Electromedical & Electrotherapeutic Apparatus

TransMedics Group, Inc.

Quality

9.7

out of 10

Value Trap

SAFE

Price

$67.20

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	STXS Fair Value	STXS Upside	TMDX Fair Value	TMDX Upside
Bayesian DCF	Intrinsic	$0.47	-76.1%	$61.34	-8.7%
Earnings Power Value	Intrinsic	$0.74	-61.8%	$41.29	-38.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for STXS vs TMDX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

STXS vs TMDX — Which Stock Is More Undervalued?

TMDX scores higher with a 9.7/10 quality rating vs STXS's 6.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Stereotaxis, Inc. (STXS) and TransMedics Group, Inc. (TMDX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

STXS currently trades at $1.98 with a QOC of 6.0/10, while TMDX trades at $67.20 with a QOC of 9.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).